The Xpert Carba-R QC Panel M219 is intended for in vitro use as a quality control to monitor the detection and differentiation of 5 beta-lactamase gene sequences (blaKPC, blaNDM, blaVIM, blaOXA-48, and blaIMP-1) when tested by the Cepheid Xpert Carba-R Assay on the GeneXpert instrument.
The gene sequences are associated with carbapenem-non-susceptibility in gram-negative bacteria. The global spread of carbapenem non-susceptible bacteria is a critical public health issue. 1,2 These bacteria are often resistant to all beta-lactam agents and frequently are co-resistant to multiple classes of other antimicrobial agents, leaving very few treatment options.
The Xpert Carba-R QC Panel M219 is intended for in vitro use as a quality control to monitor the detection and differentiation of 5 beta-lactamase gene sequences (blaKPC, blaNDM, blaVIM, blaOXA-48, and blaIMP-1) when tested by the Cepheid Xpert Carba-R Assay on the GeneXpert instrument.
The gene sequences are associated with carbapenem-non-susceptibility in gram-negative bacteria. The global spread of carbapenem non-susceptible bacteria is a critical public health issue. 1,2 These bacteria are often resistant to all beta-lactam agents and frequently are co-resistant to multiple classes of other antimicrobial agents, leaving very few treatment options.
The Xpert Carba-R QC Panel M219 is intended for in vitro use as a quality control to monitor the detection and differentiation of 5 beta-lactamase gene sequences (blaKPC, blaNDM, blaVIM, blaOXA-48, and blaIMP-1) when tested by the Cepheid Xpert Carba-R Assay on the GeneXpert instrument.
The gene sequences are associated with carbapenem-non-susceptibility in gram-negative bacteria. The global spread of carbapenem non-susceptible bacteria is a critical public health issue. 1,2 These bacteria are often resistant to all beta-lactam agents and frequently are co-resistant to multiple classes of other antimicrobial agents, leaving very few treatment options.
The Xpert Carba-R QC Panel M219 is intended for in vitro use as a quality control to monitor the detection and differentiation of 5 beta-lactamase gene sequences (blaKPC, blaNDM, blaVIM, blaOXA-48, and blaIMP-1) when tested by the Cepheid Xpert Carba-R Assay on the GeneXpert instrument.
The gene sequences are associated with carbapenem-non-susceptibility in gram-negative bacteria. The global spread of carbapenem non-susceptible bacteria is a critical public health issue. 1,2 These bacteria are often resistant to all beta-lactam agents and frequently are co-resistant to multiple classes of other antimicrobial agents, leaving very few treatment options.
The Xpert Carba-R QC Panel M219 is intended for in vitro use as a quality control to monitor the detection and differentiation of 5 beta-lactamase gene sequences (blaKPC, blaNDM, blaVIM, blaOXA-48, and blaIMP-1) when tested by the Cepheid Xpert Carba-R Assay on the GeneXpert instrument.
The gene sequences are associated with carbapenem-non-susceptibility in gram-negative bacteria. The global spread of carbapenem non-susceptible bacteria is a critical public health issue. 1,2 These bacteria are often resistant to all beta-lactam agents and frequently are co-resistant to multiple classes of other antimicrobial agents, leaving very few treatment options.
The Xpert Carba-R QC Panel M219 is intended for in vitro use as a quality control to monitor the detection and differentiation of 5 beta-lactamase gene sequences (blaKPC, blaNDM, blaVIM, blaOXA-48, and blaIMP-1) when tested by the Cepheid Xpert Carba-R Assay on the GeneXpert instrument.
The gene sequences are associated with carbapenem-non-susceptibility in gram-negative bacteria. The global spread of carbapenem non-susceptible bacteria is a critical public health issue. 1,2 These bacteria are often resistant to all beta-lactam agents and frequently are co-resistant to multiple classes of other antimicrobial agents, leaving very few treatment options.